Lupus erythematosus manifestations exacerbated by etanercept therapy in a patient with mixed connective tissue disease.
Richez
C
C
Blanco
P
P
Dumoulin
C
C
Schaeverbeke
T
T
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001168:Arthritis / Q000209:etiology / Q000473:pathology; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced / Q000209:etiology / Q000473:pathology*; D008947:Mixed Connective Tissue Disease / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins / Q000009:adverse effects*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D028761:Withholding Treatment
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept